Key terms

About GOSS

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest GOSS news

Apr 04 4:21pm ET Gossamer Bio assumed with an Outperform at Wedbush by TipRanks Apr 04 12:10pm ET Piper Sandler pharmaceuticals analysts hold an analyst/industry conference call by TipRanks Mar 21 9:00am ET Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR) by TipRanks Mar 13 6:55am ET Piper Sandler Sticks to Its Buy Rating for Gossamer Bio (GOSS) by TipRanks Mar 12 4:13pm ET Gossamer Bio Welcomes New Board Members, Enhances Leadership by TipRanks Mar 11 2:45am ET Barclays Keeps Their Hold Rating on Gossamer Bio (GOSS) by TipRanks Mar 06 11:19pm ET Optimistic Buy Rating for Gossamer Bio Amidst Progress in PAH Treatment Market by TipRanks Mar 06 7:55am ET Strong Buy Rating on Gossamer Bio Amidst Seralutinib’s Promising Trials and Solid Financials by TipRanks Mar 05 8:15pm ET Gossamer Bio Earns ‘Buy’ Rating from Analyst Citing Progress in Seralutinib Trials and Strategic Market Expansion by TipRanks Mar 05 6:15pm ET Maintained Buy Rating on Gossamer Bio Amidst Anticipated Phase 3 PROSERA Trial Results by TipRanks Mar 05 7:40am ET Gossamer Bio reports Q4 EPS (21c), consensus (21c) by TipRanks Jan 08 6:30am ET Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Neurogene (NGNE) and Gossamer Bio (GOSS) by TipRanks Jan 08 6:23am ET Gossamer Bio price target raised to $10 from $5 at H.C. Wainwright by TipRanks

No recent press releases are available for GOSS

GOSS Financials

1-year income & revenue

Key terms

GOSS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

GOSS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming